Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib (HKI-272) After Trastuzumab In Women With Early-Stage HER-2/Neu Overexpressed/Amplified Breast Cancer
Conditions
Interventions
neratinib
placebo
Locations
494
United States
Anniston Oncology
Anniston, Alabama, United States
Birmingham Hematology and Oncology Associates, LLC
Birmingham, Alabama, United States
Arizona Oncology Associates, PC - HAL
Phoenix, Arizona, United States
Arizona Oncology Associates, PC - NAHOA
Sedona, Arizona, United States
Arizona Oncology Associates
Tucson, Arizona, United States
Arizona Cancer Center
Tucson, Arizona, United States
Start Date
July 9, 2009
Primary Completion Date
August 21, 2014
Completion Date
October 4, 2019
Last Updated
June 11, 2021
NCT04541381
NCT05468034
NCT03137095
NCT07040891
NCT07547774
NCT04852887
Lead Sponsor
Puma Biotechnology, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions